Literature DB >> 16463202

Rare mutation of PIK3CA in meningiomas.

Jesse Chung-sean Pang, Nellie Yuk Fei Chung, Norman Hok Ling Chan, Wai Sang Poon, Teresa Thomas, Ho-keung Ng.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16463202     DOI： 10.1007/s00401-005-0021-0

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  9 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

2.  Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.

Authors:  Elias A El-Habr; Georgia Levidou; Eleni-Andriana Trigka; Joanna Sakalidou; Christina Piperi; Ilenia Chatziandreou; Anastasia Spyropoulou; Rigas Soldatos; Georgia Tomara; Kalliopi Petraki; Vassilis Samaras; Athanasios Zisakis; Vassilis Varsos; George Vrettakos; Efstathios Boviatsis; Efstratios Patsouris; Angelica A Saetta; Penelope Korkolopoulou
Journal:  Virchows Arch       Date:  2014-08-22       Impact factor: 4.064

3.  PIK3CA mutations in meningioma.

Authors:  Gelareh Zadeh; Shirin Karimi; Kenneth D Aldape
Journal:  Neuro Oncol       Date:  2016-05       Impact factor: 12.300

4.  NF2 Alteration/22q Loss Is Associated with Recurrence in WHO Grade 1 Sphenoid Wing Meningiomas.

Authors:  Yu Sakai; Satoru Miyawaki; Yu Teranishi; Atsushi Okano; Kenta Ohara; Hiroki Hongo; Daiichiro Ishigami; Daisuke Shimada; Jun Mitsui; Hirofumi Nakatomi; Nobuhito Saito
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

Review 5.  The PIK3CA gene as a mutated target for cancer therapy.

Authors:  John P Gustin; David P Cosgrove; Ben Ho Park
Journal:  Curr Cancer Drug Targets       Date:  2008-12       Impact factor: 3.428

6.  Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.

Authors:  Malak Abedalthagafi; Wenya Linda Bi; Ayal A Aizer; Parker H Merrill; Ryan Brewster; Pankaj K Agarwalla; Marc L Listewnik; Dora Dias-Santagata; Aaron R Thorner; Paul Van Hummelen; Priscilla K Brastianos; David A Reardon; Patrick Y Wen; Ossama Al-Mefty; Shakti H Ramkissoon; Rebecca D Folkerth; Keith L Ligon; Azra H Ligon; Brian M Alexander; Ian F Dunn; Rameen Beroukhim; Sandro Santagata
Journal:  Neuro Oncol       Date:  2016-01-28       Impact factor: 12.300

7.  Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies.

Authors:  Ahmad A Nazem; Jacob Ruzevick; Manuel J Ferreira
Journal:  Oncotarget       Date:  2020-12-08

Review 8.  Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.

Authors:  Atsushi Okano; Satoru Miyawaki; Yu Teranishi; Kenta Ohara; Hiroki Hongo; Yu Sakai; Daiichiro Ishigami; Hirofumi Nakatomi; Nobuhito Saito
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-07-22       Impact factor: 2.036

9.  EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas.

Authors:  Mateusz Bujko; Paulina Kober; Andrzej Tysarowski; Ewa Matyja; Tomasz Mandat; Wiesław Bonicki; Janusz Aleksander Siedlecki
Journal:  Oncol Lett       Date:  2014-04-07       Impact factor: 2.967
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.